Trial Profile
A prospective, observational study evaluating preferred choice of treatment between Nintedanib and pirfenidone for idiopathic pulmonary fibrosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2020
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 20 May 2020 Results (N=78), assessing factors Influencing patients' preferred Choice of antifibrotic, presented at the 116th International Conference of the American Thoracic Society
- 12 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society